ArticleGut microbes
Gut microbiota as prognosis markers for patients with HBV-related acute-on-chronic liver failure.
Article in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05786859 (The Efficacy and Safety of Rifaximin In The Treatment of HBV Associated Acute-on-Chronic Liver Failure Patients With Mild to Moderate Hepatic Encephalopathy), which is not on this map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Efficacy and Safety of Rifaximin In The Treatment of HBV Associated Acute-on-Chronic Liver Failure Patients With Mild to Moderate Hepatic Encephalopathy
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- A Systematic Review of Microbiota in Cirrhosis: A Change Towards a More Pathogenic Predisposition.International journal of molecular sciences · 2025Pooled it
- Characterization of the intrahepatic microbiome in patients with HBV-related end-stage liver disease.Virulence · 2026Article
- Bifidobacterium longum subsp. infantis CCFM1445 Promotes Bone Growth in Growing Mice Via Modulating Gut Microbiota and Arginine Metabolism Pathway.Probiotics and antimicrobial proteins · 2026Article
- Inflammatory gut-liver crosstalk: mechanisms and therapeutic targets.Experimental & molecular medicine · 2026Review
- Short-chain Fatty Acids and Bile Acids Signaling in Chronic Hepatitis B.Journal of clinical and translational hepatology · 2026Review
- Potential contribution of intestinal commensal microbiota to the progression of liver failure.Chinese medical journal · 2026Article
- HBV and the Microbiome-PubMed Database Literature Review.Infectious disease reports · 2026Review
- Gut microbiota dysbiosis aggravates liver injury in acute-on-chronic liver failure through D-lactate accumulation.Frontiers in microbiology · 2026Article
- Article
- Gut microbiota links to histological damage in chronic HBV infection patients and aggravates fibrosis via fecal microbiota transplantation in mice.Microbiology spectrum · 2025Article
- Machine learning algorithms reveal gut microbiota signatures associated with chronic hepatitis B-related hepatic fibrosis.World journal of gastroenterology · 2025Article
- Faecalibacterium prausnitzii-derived outer membrane vesicles reprogram gut microbiota metabolism to alleviate Porcine Epidemic Diarrhea Virus infection.Microbiome · 2025Article
- Short-Chain Fatty Acids: Promising Therapeutic Targets for Respiratory Syncytial Virus Infection.Clinical reviews in allergy & immunology · 2025Review
- Species-level enterosignatures predict clinical phenotypes in chronic hepatitis B and causal triangulation of gut-metabolite-CHB interactions.Frontiers in microbiology · 2025Article
- D-glucaro-1,4-lactone alleviates acetaminophen-induced hepatotoxicity in mice via modulating gut microbiota and metabolites associated withFrontiers in pharmacology · 2025Article
- Potential role of gut bacteria in the development of hepatocellular carcinoma.Access microbiology · 2025Article
- Gut microbiota in liver diseases: initiation, development and therapy.Frontiers in medicine · 2025Review
- Is health, growth and development impaired in children who are Hepatitis B-exposed but uninfected?PLOS global public health · 2025Review
- The role of bacterial outer membrane vesicles in inflammatory response of acute-on-chronic liver failure.Frontiers in microbiology · 2025Review
- Gut microbiota and metabolite profiles in HBV cirrhosis with persistent liver enzyme abnormalities.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota in the hepatitis B virus related acute-on-chronic liver failure (HBV-ACLF) is poorly defined. We aim to uncover the characteristics of the gut microbiota in HBV-ACLF and in other HBV associated pathologies. We analyzed the gut microbiome in patients with HBV-ACLF or other HBV associated pathologies and healthy individuals by 16S rRNA sequencing and metagenomic sequencing of fecal samples. 212 patients with HBV-ACLF, 252 with chronic hepatitis B (CHB), 162 with HBV-associated cirrhosis (HBV-LC) and 877 healthy individuals were recruited for the study. CHB and HBV-LC patients are grouped as HBV-Other. We discovered striking differences in the microbiome diversity between the HBV-ACLF, HBV-Other and healthy groups using 16S rRNA sequencing. The ratio of cocci to bacilli was significantly elevated in the HBV-ACLF group compared with healthy group. Further analysis within the HBV-ACLF group identified 52 genera showing distinct richness within the group where
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.